Payment overview · 2025
General Payments
$343.18
20 reported records · 11 companies
Healthcare provider profile · identity verified
Scott T Armstrong, DO
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, IN · NPI 1861402760
Verified facts
What the public records show
CMS Open Payments records show Scott T Armstrong, DO received $343.18 in general payments during 2025 across 20 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.88 | 20.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.81 | 15.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.83 | 13.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.62 | 11.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.68 | 10.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.12 | 5.9% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $19.04 | 5.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.90 | 4.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.37 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.37 | 4.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.56 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $343.18 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.88 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.52 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.81 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.59 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.59 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 45 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 56 |
| Lisinopril | Lisinopril | 211 | 56 |
| Omeprazole | Omeprazole | 158 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 147 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 36 |
| Metformin Hcl | Metformin Hcl | 138 | 42 |
| Losartan Potassium | Losartan Potassium | 137 | 41 |
| Gabapentin | Gabapentin | 119 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 28 |
| Spironolactone | Spironolactone | 102 | 31 |
| Ozempic | Semaglutide | 101 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 34 |
| Allopurinol | Allopurinol | 97 | 24 |
| Carvedilol | Carvedilol | 96 | 27 |
| Sertraline Hcl | Sertraline Hcl | 94 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 16 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Farxiga | Dapagliflozin Propanediol | 67 | 15 |
| Potassium Chloride | Potassium Chloride | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 27 |
| Bupropion Xl | Bupropion Hcl | 65 | 20 |
| Simvastatin | Simvastatin | 64 | 14 |
| Tramadol Hcl | Tramadol Hcl | 64 | 12 |
| Furosemide | Furosemide | 62 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 15 |
| Jardiance | Empagliflozin | 59 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 18 |
| Meloxicam | Meloxicam | 51 | 16 |
| Famotidine | Famotidine | 48 | 14 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Eliquis | Apixaban | 45 | 13 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Atenolol | Atenolol | 43 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Dutasteride | Dutasteride | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 14 |
| Alprazolam | Alprazolam | 37 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 11 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $343.18 · 20 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, Korlym, NURTEC ODT, QULIPTA, Qelbree, REXULTI, SLYND, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error